Patents by Inventor Marc Labelle

Marc Labelle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptidyl derivatives as inhibitors of pro-apoptotic cysteine proteinases
    Patent number: 5798442
    Abstract: Compounds having the formula I:R.sup.1 COAA.sup.1 AA.sup.2 AA.sup.3 NHYare inhibitors of apopain, an enzyme involved in the process of apoptosis. These compounds are useful as research tools as well as in the treatment of any condition in which reduced apoptosis would be beneficial, including immune deficiency syndromes (including AIDS), type I diabetes, pathogenic infections, cardiovascular and neurological injury, alopecia, aging, Parkinson's disease and Alzheimer's disease.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: August 25, 1998
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Michel Gallant, Marc Labelle, Yves Gareau, Donald W. Nicholson
  • Heteroaryl diol acids as leukotriene antagonists
    Patent number: 5750539
    Abstract: Compounds of Formula I: ##STR1## are antagonists of the actions of leukotrienes. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 12, 1998
    Assignee: Merck Frosst Canada
    Inventors: Yves Gareau, Claude Dufresne, Marc Labelle, James Yergey, Xin Xu, Deborah Nicoll-Griffith, Nathalie Chauret, Laird Trimble
  • Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
    Patent number: 5565473
    Abstract: Compounds having the formula I: ##STR1## are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.
    Type: Grant
    Filed: February 23, 1995
    Date of Patent: October 15, 1996
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Michel L. Belley, Serge Leger, Marc Labelle, Patrick Roy, Yi B. Xiang, Daniel Guay
  • Indole derivatives with affinity for the cannabinoid receptor
    Patent number: 5532237
    Abstract: Disclosed are indole derivatives having activity on the cannabinoid receptors and the methods of their preparation. The compounds are useful for lowering ocular intra ocular pressure and treating glaucoma because of the activity on the cannabinoid receptor.
    Type: Grant
    Filed: February 15, 1995
    Date of Patent: July 2, 1996
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Michel Gallant, Yves Gareau, Daniel Guay, Marc Labelle, Petpiboon Prasit
  • Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists
    Patent number: 5472964
    Abstract: Compounds having the formula I: ##STR1## are antagonists of the actions of leukotrienes. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.
    Type: Grant
    Filed: June 16, 1994
    Date of Patent: December 5, 1995
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Robert N. Young, Marc Labelle, Yves Leblanc, Yi B. Xiang, Cheuk K. Lau, Claude Dufresne, Yves Gareau
  • Saturated hydroxyalkylquinoline acids as leukotriene antagonists
    Patent number: 5428033
    Abstract: Compounds having the formula I: ##STR1## are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.
    Type: Grant
    Filed: October 10, 1991
    Date of Patent: June 27, 1995
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Michel L. Belley, Serge Leger, Patrick Roy, Yi B. Xiang, Marc Labelle
  • Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
    Patent number: 5270324
    Abstract: Compounds having the formula I: ##STR1## are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.
    Type: Grant
    Filed: April 10, 1992
    Date of Patent: December 14, 1993
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Robert Zamboni, Daniel Guay, Marc LaBelle
  • Hydroxyalkylquinoline ether acids as leukotriene antagonists
    Patent number: 5266568
    Abstract: Compounds having the formula I: ##STR1## are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.
    Type: Grant
    Filed: October 10, 1991
    Date of Patent: November 30, 1993
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Michel L. Belley, Yves LeBlanc, Marc Labelle